Novartis signs agreement to acquire SNV4818 from Synnovation Therapeutics. SNV4818 is a PI3Kα inhibitor that is highly potent and selective against pan-mutants, including the H1047X and E545/542X mutations. This orally administered medicine is designed to treat tumors with activating PIK3CA mutations, particularly breast cancer and other solid tumors. The deal includes an upfront payment of $2 billion, with a total value of up to $3 billion. SNV4818 is Synnovation's second clinical program; their lead candidate SNV1521 entered Phase I in January 2024. SNV4818 is currently in a Phase I clinical trial (NCT06736704) being tested as monotherapy and in combination with fulvestrant in patients with advanced solid tumors. The exam is recruitment and takes place in the USA, Canada and Australia. Synnovation Therapeutics is a Delaware-based precision medicine company.[1][2][3][5][7][8]